HomeCompareONCT vs SPHD

ONCT vs SPHD: Dividend Comparison 2026

ONCT yields 379.79% · SPHD yields 4.33%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ONCT wins by $7846.56M in total portfolio value
10 years
ONCT
ONCT
● Live price
379.79%
Share price
$0.53
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7846.59M
Annual income
$5,169,197,450.71
Full ONCT calculator →
SPHD
SPHD
● Live price
4.33%
Share price
$49.34
Annual div
$2.14
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$571.32
Full SPHD calculator →

Portfolio growth — ONCT vs SPHD

📍 ONCT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodONCTSPHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ONCT + SPHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ONCT pays
SPHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ONCT
Annual income on $10K today (after 15% tax)
$32,282.57/yr
After 10yr DRIP, annual income (after tax)
$4,393,817,833.10/yr
SPHD
Annual income on $10K today (after 15% tax)
$367.92/yr
After 10yr DRIP, annual income (after tax)
$485.62/yr
At 15% tax rate, ONCT beats the other by $4,393,817,347.48/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ONCT + SPHD for your $10,000?

ONCT: 50%SPHD: 50%
100% SPHD50/50100% ONCT
Portfolio after 10yr
$3923.31M
Annual income
$2,584,599,011.01/yr
Blended yield
65.88%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ONCT buys
0
SPHD buys
0
No recent congressional trades found for ONCT or SPHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricONCTSPHD
Forward yield379.79%4.33%
Annual dividend / share$2.00$2.14
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$7846.59M$26.5K
Annual income after 10y$5,169,197,450.71$571.32
Total dividends collected$7596.65M$5.1K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: ONCT vs SPHD ($10,000, DRIP)

YearONCT PortfolioONCT Income/yrSPHD PortfolioSPHD Income/yrGap
1← crossover$48,679$37,979.49$11,133$432.85+$37.5KONCT
2$224,874$172,787.13$12,363$450.36+$212.5KONCT
3$986,585$745,969.70$13,695$467.39+$972.9KONCT
4$4,114,314$3,058,668.09$15,138$483.90+$4.10MONCT
5$16,323,283$11,920,966.77$16,697$499.88+$16.31MONCT
6$61,667,489$44,201,576.55$18,382$515.31+$61.65MONCT
7$222,048,216$156,064,002.73$20,198$530.17+$222.03MONCT
8$762,773,776$525,182,185.09$22,157$544.46+$762.75MONCT
9$2,502,234,339$1,686,066,398.09$24,266$558.18+$2502.21MONCT
10$7,846,588,193$5,169,197,450.71$26,536$571.32+$7846.56MONCT

ONCT vs SPHD: Complete Analysis 2026

ONCTStock

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.

Full ONCT Calculator →

SPHDETF

The Invesco S&P 500 High Dividend Low Volatility ETF (Fund) is based on the S&P 500 Low Volatility High Dividend Index (Index). The Fund will invest at least 90% of its total assets in common stocks that comprise the Index. Standard & Poor's compiles, maintains and calculates the Index, which is composed of 50 securities traded on the S&P 500 Index that historically have provided high dividend yields and low volatility. The Fund and the Index are rebalanced and reconstituted semi-annually, in January and July.

Full SPHD Calculator →
📬

Get this ONCT vs SPHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ONCT vs SCHDONCT vs JEPIONCT vs OONCT vs KOONCT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.